Hisamitsu gains close to 90% of Noven in first tender
This article was originally published in Scrip
Executive Summary
Hisamitsu had secured an 87.4% holding in Noven Pharmaceuticals at the August 19th close of its initial tender offer for the US firm, paving the way for a full acquisition.